Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Immunotherapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Survival: 9.6 months
Toxicity Grade: 4
Treatments: Immunotherapy
Country: United States
City/State/Province: New York, NY
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 10/2013

This study involved 39 metastatic uveal melanoma patients with a median age of 61 years, 59% of whom were male.

Patients were treated with the immune therapy agent ipilimumab, which is an antibody to the CTLA-4 protein and enhances the immune response against cancer cells.

The most severe toxicities were of grade 4 and included grade 3-4 colitis (inflammation of the colon) and liver and pancreatic toxicities.

The median overall survival was 9.6 months.

Some of the authors have received funding from Bristol Myers Squibb (makers of ipilimumab).

Correspondence: Dr. Richard D. Carvajal; email:

E-mail to a Friend Email Physician More Information